Cellular therapies and tissue engineering company Lattice Biologics Ltd (TSX-V:LBL) (OTCBB:LBLTF) stated on Monday that it recorded a net loss of USD0.3m (USD0.00 per share) for the third quarter of 2020.
This is flat when compared with a net loss of USD0.3m (USD0.00 per share) for the same period in the prior year.
Gross profit of USD0.1m was recorded for the three months ended 30 June 2020, down over USD0.2m in the comparable previous year.
Sales of USD0.5m were announced for the three months ended 30 June 2020, a dip from sales of USD0.4m in the third quarter of 2019.
Lattice Biologics' CEO Guy Cook said the company has continued to maintain its relationship with critical customers during the COVID-19 pandemic, with sales increasing 13% year over year. It expects revenues to continue to grow to the USD3.5 to 4.0m range for 2021.
Thermo Fisher Scientific to acquire Clario Holdings, expanding clinical data capabilities
Nanoform and Revio Therapeutics partner to develop long-acting hydrogel therapy for glioma
Cumberland Pharmaceuticals adds FDA-approved oral capsule for H. pylori to commercial portfolio
IP Group positions for future royalties following Pfizer's USD7.3bn acquisition of Metsera
AstraZeneca strikes landmark drug pricing deal with US Government
Fusion Antibodies secures multi-target humanisation contract with global pharmaceutical client
Genmab to acquire Merus in USD8bn deal to strengthen oncology pipeline
Wolters Kluwer launches UpToDate Expert AI to deliver trusted GenAI clinical decision support
CVS Health declares unchanged quarterly dividend
ALK partners with GenSci to expand allergy immunotherapy market in China
Curatis secures Swiss distribution deal with Phoenix Labs
Innocan Pharma reports 'positive swing' in operating profitability for first half of 2025
Wolters Kluwer boosts medical research efficiency with Ovid AI summarisation